Leonid Gorelik

Biotech Park — India

Medicine · Health Sciences

31h-index9.5kcitations52works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Polyomavirus and related diseases(17), T-cell and B-cell Immunology(13), Immune Cell Function and Interaction(12), Full-Duplex Wireless Communications(11), Immunotherapy and Immune Responses(10)

Publications52 total

Alterations in glutamate, arginine, and energy metabolism characterize cerebrospinal fluid and plasma metabolome of persons with HIV-associated dementia
AIDS·2023
112 Incidence of postpartum depression (PPD) in SARS-CoV-2 positive mothers who underwent maternal-neonatal separation
American Journal of Obstetrics and Gynecology·2021· 2 citedOpen Access
Abstract 5790: TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models
Cancer Research·2018
A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia
Biology of Blood and Marrow Transplantation·2018· 68 cited
Abstract 4606: Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301
Cancer Research·2017· 7 cited
Distribution and Quantity of Sites of John Cunningham Virus Persistence in Immunologically Healthy Patients
JAMA Neurology·2017· 21 cited
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
Neurology·2015· 50 citedOpen Access
Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1
mAbs·2015· 20 citedOpen Access
CD62L (L-selectin) is Not a Reliable Biomarker for Predicting Risk of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients (P4.039)
Neurology·2015· 4 cited
Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission
Blood·2014· 7 cited
Human glial chimeric mice reveal astrocytic dependence of JC virus infection
Journal of Clinical Investigation·2014· 82 citedOpen Access
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes
Journal of NeuroVirology·2013· 162 citedOpen Access
Reply
Annals of Neurology·2012
Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma
Journal of Clinical Virology·2011· 21 cited
Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
The Journal of Infectious Diseases·2011· 122 citedOpen Access
Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor Specificity
The Journal of Infectious Diseases·2011· 157 citedOpen Access
Assay design and sample collection can affect anti‐John Cunningham virus antibody detection
Annals of Neurology·2010· 14 cited
Evaluation of the Incidence of Anti-JC Virus Antibodies in a Cohort of Natalizumab-Treated Patients
The American Journal of Gastroenterology·2010
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Annals of Neurology·2010· 430 cited
Assessment of JC virus DNA in blood and urine from natalizumab‐treated patients
Annals of Neurology·2010· 102 cited
page 1 of 3Next →

Frequent Co-authors

Richard A. Flavell(13), Kenneth J. Simon(8), Susan Goelz(6), Margalit B. Mokyr(6), Meena Subramanyam(5), Susan L. Kalled(4), Margot Brickelmaier(4), Tatiana Plavina(4), Sarah A. Bixler(3), Alfred Sandrock(3), Alexey A. Lugovskoy(3), Paola Cinque(3), John P. Carulli(3), Ralph Weissleder(2), Michaela Lerner(2), Mary Crossman(2), Brian Schlain(2), Anne E. Cheung(2), Ling Ling Chen(2), Melissa Berman(2)